Clinical features of patients with novel Yersinia species

Conor G. Loftus, Gavin C. Harewood, Franklin R. Cockerill, Joseph A Murray

Research output: Contribution to journalArticle

21 Citations (Scopus)

Abstract

Our purpose was to describe the clinical features of patients with novel Yersinia species. Between 1985 and 1999; 194 patients had yersinia species isolated from stool specimens, 38 (20%) had non-Yersinia enterocolitica species; 12 (32%) had Yersinia intermedia, 7 (18%) Yersinia fredericksenii, 3 (8%) Yersinia kristensenii, and the remaining 16 (42%) were unclassified non-Yersinia enterocolitica species. The most common presenting symptom was diarrhea alone in 10 (26.3%) patients. Symptoms persisted for >1 month in 54% of cases; 21% had symptoms for <1 week; 18 (47%) patients were taking corticosteroids, acid suppressants, and/or antibiotics when Yersinia was isolated. An immunocompromised state was present in 11 (29%) patients. An immunocompromised host and administration of acid suppressants predicted persistence of symptoms for >1 month. Most [27 (71%)] patients received no treatment; 5 (13%) received antibiotics. In conclusion, novel non-Yersinia enterocolitica species, including Yersinia intermedia, Y. fredericksenii, and Y. kristensenii may represent up to 20% of all Yersinia isolates. Diarrhea is the most common symptom.

Original languageEnglish (US)
Pages (from-to)2805-2810
Number of pages6
JournalDigestive Diseases and Sciences
Volume47
Issue number12
DOIs
StatePublished - Dec 1 2002

Fingerprint

Yersinia
Diarrhea
Anti-Bacterial Agents

Keywords

  • Abdominal pain
  • Enteric pathogens
  • Infectious diarrhea
  • Novel species
  • Yersinia

ASJC Scopus subject areas

  • Gastroenterology

Cite this

Clinical features of patients with novel Yersinia species. / Loftus, Conor G.; Harewood, Gavin C.; Cockerill, Franklin R.; Murray, Joseph A.

In: Digestive Diseases and Sciences, Vol. 47, No. 12, 01.12.2002, p. 2805-2810.

Research output: Contribution to journalArticle

Loftus, Conor G. ; Harewood, Gavin C. ; Cockerill, Franklin R. ; Murray, Joseph A. / Clinical features of patients with novel Yersinia species. In: Digestive Diseases and Sciences. 2002 ; Vol. 47, No. 12. pp. 2805-2810.
@article{528cf61188154e4789cf593c41af58e8,
title = "Clinical features of patients with novel Yersinia species",
abstract = "Our purpose was to describe the clinical features of patients with novel Yersinia species. Between 1985 and 1999; 194 patients had yersinia species isolated from stool specimens, 38 (20{\%}) had non-Yersinia enterocolitica species; 12 (32{\%}) had Yersinia intermedia, 7 (18{\%}) Yersinia fredericksenii, 3 (8{\%}) Yersinia kristensenii, and the remaining 16 (42{\%}) were unclassified non-Yersinia enterocolitica species. The most common presenting symptom was diarrhea alone in 10 (26.3{\%}) patients. Symptoms persisted for >1 month in 54{\%} of cases; 21{\%} had symptoms for <1 week; 18 (47{\%}) patients were taking corticosteroids, acid suppressants, and/or antibiotics when Yersinia was isolated. An immunocompromised state was present in 11 (29{\%}) patients. An immunocompromised host and administration of acid suppressants predicted persistence of symptoms for >1 month. Most [27 (71{\%})] patients received no treatment; 5 (13{\%}) received antibiotics. In conclusion, novel non-Yersinia enterocolitica species, including Yersinia intermedia, Y. fredericksenii, and Y. kristensenii may represent up to 20{\%} of all Yersinia isolates. Diarrhea is the most common symptom.",
keywords = "Abdominal pain, Enteric pathogens, Infectious diarrhea, Novel species, Yersinia",
author = "Loftus, {Conor G.} and Harewood, {Gavin C.} and Cockerill, {Franklin R.} and Murray, {Joseph A}",
year = "2002",
month = "12",
day = "1",
doi = "10.1023/A:1021081911456",
language = "English (US)",
volume = "47",
pages = "2805--2810",
journal = "Digestive Diseases and Sciences",
issn = "0163-2116",
publisher = "Springer New York",
number = "12",

}

TY - JOUR

T1 - Clinical features of patients with novel Yersinia species

AU - Loftus, Conor G.

AU - Harewood, Gavin C.

AU - Cockerill, Franklin R.

AU - Murray, Joseph A

PY - 2002/12/1

Y1 - 2002/12/1

N2 - Our purpose was to describe the clinical features of patients with novel Yersinia species. Between 1985 and 1999; 194 patients had yersinia species isolated from stool specimens, 38 (20%) had non-Yersinia enterocolitica species; 12 (32%) had Yersinia intermedia, 7 (18%) Yersinia fredericksenii, 3 (8%) Yersinia kristensenii, and the remaining 16 (42%) were unclassified non-Yersinia enterocolitica species. The most common presenting symptom was diarrhea alone in 10 (26.3%) patients. Symptoms persisted for >1 month in 54% of cases; 21% had symptoms for <1 week; 18 (47%) patients were taking corticosteroids, acid suppressants, and/or antibiotics when Yersinia was isolated. An immunocompromised state was present in 11 (29%) patients. An immunocompromised host and administration of acid suppressants predicted persistence of symptoms for >1 month. Most [27 (71%)] patients received no treatment; 5 (13%) received antibiotics. In conclusion, novel non-Yersinia enterocolitica species, including Yersinia intermedia, Y. fredericksenii, and Y. kristensenii may represent up to 20% of all Yersinia isolates. Diarrhea is the most common symptom.

AB - Our purpose was to describe the clinical features of patients with novel Yersinia species. Between 1985 and 1999; 194 patients had yersinia species isolated from stool specimens, 38 (20%) had non-Yersinia enterocolitica species; 12 (32%) had Yersinia intermedia, 7 (18%) Yersinia fredericksenii, 3 (8%) Yersinia kristensenii, and the remaining 16 (42%) were unclassified non-Yersinia enterocolitica species. The most common presenting symptom was diarrhea alone in 10 (26.3%) patients. Symptoms persisted for >1 month in 54% of cases; 21% had symptoms for <1 week; 18 (47%) patients were taking corticosteroids, acid suppressants, and/or antibiotics when Yersinia was isolated. An immunocompromised state was present in 11 (29%) patients. An immunocompromised host and administration of acid suppressants predicted persistence of symptoms for >1 month. Most [27 (71%)] patients received no treatment; 5 (13%) received antibiotics. In conclusion, novel non-Yersinia enterocolitica species, including Yersinia intermedia, Y. fredericksenii, and Y. kristensenii may represent up to 20% of all Yersinia isolates. Diarrhea is the most common symptom.

KW - Abdominal pain

KW - Enteric pathogens

KW - Infectious diarrhea

KW - Novel species

KW - Yersinia

UR - http://www.scopus.com/inward/record.url?scp=0036907268&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0036907268&partnerID=8YFLogxK

U2 - 10.1023/A:1021081911456

DO - 10.1023/A:1021081911456

M3 - Article

C2 - 12498305

AN - SCOPUS:0036907268

VL - 47

SP - 2805

EP - 2810

JO - Digestive Diseases and Sciences

JF - Digestive Diseases and Sciences

SN - 0163-2116

IS - 12

ER -